Patents by Inventor Joseph Collard

Joseph Collard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
    Patent number: 11697814
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: July 11, 2023
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
    Patent number: 11408004
    Abstract: The present invention relates to antisense oligonucleotide that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: August 9, 2022
    Assignee: CURNA, INC.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
    Patent number: 11390868
    Abstract: The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: July 19, 2022
    Assignee: CURNA, INC.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
    Publication number: 20220195439
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.
    Type: Application
    Filed: December 10, 2021
    Publication date: June 23, 2022
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
    Patent number: 11339394
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Collagen gene, in particular, by targeting natural antisense polynucleotides of a Collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Collagen genes.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: May 24, 2022
    Assignee: CURNA, INC.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
    Patent number: 10995334
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 4, 2021
    Assignee: CuRNA Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
    Patent number: 10934546
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 2, 2021
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
    Patent number: 10876117
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 29, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
    Patent number: 10793857
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: October 6, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon, Carlos Coito, Jane H. Hsiao
  • TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
    Publication number: 20200291407
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 17, 2020
    Inventors: Joseph COLLARD, Olga Khorkova Sherman, Carlos Coito
  • Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
    Patent number: 10696966
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sex Hormone Binding Globulia (SHBG), in particular, by targeting natural antisense polynucleotides of Sex Hormone Binding Globulin (SHBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SHBG.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: June 30, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)
    Publication number: 20200131517
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN
  • Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
    Patent number: 10604755
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: March 31, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
    Patent number: 10583128
    Abstract: Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: March 10, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Jane H. Hsiao
  • Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
    Patent number: 10563202
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: February 18, 2020
    Assignee: GuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF DOWN SYNDROME GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A DOWN SYNDROME GENE
    Publication number: 20200032263
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 30, 2020
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
    Patent number: 10519448
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonecleotides and their use in treating diseases and disorders associated with the expression of BDNF.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: December 31, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
    Patent number: 10487327
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: November 26, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
    Patent number: 10465192
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like 1 homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like 1 homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLK1.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: November 5, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
    Patent number: 10450567
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: October 22, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman